Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Effects of Ponatinib and Other Novel TKI On Growth, Survival, and Function of Neoplastic Eosinophils Carrying FIP1L1/Pdgfra

Irina Sadovnik, M.Sc., Peter Valent, MD, Els Lierman, PhD, Harald Herrmann, M.D., Barbara Peter, D.V.M., Verena Suppan, BSc, Gabriele Stefanzl, MSc, Winfried F Pickl, MD, Jan Cools, PhD, Peter Vandenberghe, MD, PhD

Blood (2012) 120 (21): 1760.

https://doi.org/10.1182/blood.V120.21.1760.1760

Published: 2012

Journal Articles

5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells,

Viviane Ghanim, M.D., Harald Herrmann, MD, Emir Hadzijusufovic, DVM, Barbara Peter, D.V.M., Katharina Blatt, M.Sc., Karina Schuch, Sabine Cerny-Reiterer, D.V.M., Irina Mirkina, PhD, Gerwin Heller, PhD, Sabine Zöchbauer-Müller, MD, Heidrun Karlic, PhD, Winfried F Pickl, MD, Peter Valent, M.D.

Blood (2011) 118 (21): 3457.

https://doi.org/10.1182/blood.V118.21.3457.3457

Published: 2011

Journal Articles

The Heat Shock Protein 32 (Hsp32)/HO-1-Targeting Drug SMA-ZnPP and the Triterpenoid CDDO-Me Exert Synergistic Growth-Inhibitory Effects on TKI-Resistant Leukemic Cells in Ph+ CML

Karoline V. Gleixner, M.D., Harald Herrmann, M.D., Katharina Blatt, M.Sc., Winfried F Pickl, MD, Marina Konopleva, MD, PhD, Gahininath Y Bharate, Michael Andreeff, M.D., Ph.D., Hiroshi Maeda, MD, Peter Valent, M.D.

Blood (2011) 118 (21): 4414.

https://doi.org/10.1182/blood.V118.21.4414.4414

Published: 2011

Journal Articles

Bosutinib Blocks Lyn and Btk Activation and Synergizes with the KIT D816V-Targeting Drug Midostaurin in Inducing Apoptosis in Neoplastic Human Mast Cells.

Karoline Veronika Gleixner, MD, Matthias Mayerhofer, MD, Gregor Hörmann, Karina Schuch, Sabine Cerny-Reiterer, MD, Barbara Peter, M.V.M, Harald Herrmann, MD, Winfried F. Pickl, MD, Christian Sillaber, Peter Valent, MD

Blood (2009) 114 (22): 1717.

https://doi.org/10.1182/blood.V114.22.1717.1717

Published: 2009

Journal Articles

Effects of Bosutinib (SKI-606) in CML: Kinase Target Profile, Effects on BCR/ABL Mutants, and Synergism with Dasatinib in T315I+ Cells

Karoline Veronika Gleixner, MD, Lily L Remsing Rix, Christian Baumgartner, Uwe Rix, Alexander Gruze, Renata Anna Meyer, M.D., Winfried F. Pickl, MD, Christian Sillaber, Martin Augustin, Jeff Till, Giulio Superti-Furga, Peter Valent, MD

Blood (2008) 112 (11): 3195.

https://doi.org/10.1182/blood.V112.11.3195.3195

Published: 2008

Journal Articles

Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL).

Renata A. Meyer, MD, Harald Herrmann, MD, Karoline V. Gleixner, MD, Alexander Gruze, Sabine Cerny-Reiterer, MD, Rainer Hubmann, PhD, Medhat Shehata, MD, Matthias Mayerhofer, MD, Wolfgang R. Sperr, MD, Winfried F. Pickl, MD, Junia V. Melo, PhD, Gahininath Y. Bharate, Ulrich Jäger, MD, Hiroshi Maeda, MD, PhD, Peter Valent, MD

Blood (2008) 112 (11): 1616.

https://doi.org/10.1182/blood.V112.11.1616.1616

Published: 2008

Journal Articles

Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax ® ) on Growth and Viability of Canine and Human Neoplastic Mast Cells

Barbara Peter, MVM, Karl J. Aichberger, MD, Karoline V. Gleixner, MD, Veronika Ferenc, MD, Alexander Gruze, Winfried F. Pickl, MD, Michael Willmann, DVM, Peter Valent, MD

Blood (2008) 112 (11): 861.

https://doi.org/10.1182/blood.V112.11.861.861

Published: 2008

Journal Articles

Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis.

Karoline V. Gleixner, MD, Mayerhofer Matthias, MD, Anja Vales, MD, Alexander Gruze, Michael Kneidinger, MD, Gregor Hoermann, Maria T. Krauth, MD, Rudin Kondo, MD, Karoline Sonneck, MD, Puchit Samorapoompichit, MD, Eva Lackner, MD, Khaled Greish, PhD, Winfried F. Pickl, MD, Christian Sillaber, MD, Christoph C. Zielinski, MD, Hiroshi Maeda, MD, Peter Valent, MD

Blood (2006) 108 (11): 4323.

https://doi.org/10.1182/blood.V108.11.4323.4323

Published: 2006

Journal Articles

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

Karoline V. Gleixner, MD, Matthias Mayerhofer, MD, Karoline Sonneck, MD, Alexander Gruze, Puchit Samorapoompichit, MD, Karl J. Aichberger, MD, Francis Y. Lee, PhD, Paul W. Manley, PhD, Doriano Fabbro, PhD, Winfried F. Pickl, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2006) 108 (11): 526.

https://doi.org/10.1182/blood.V108.11.526.526

Published: 2006

Journal Articles

Circulating B-Lymphocyte Subpopulations as Novel Biomarker for Measuring Activity of Chronic Graft-Versus-Host Disease.

David Pohlreich, MD, Hildegard T. Greinix, MD, Karin Feldmann, Ulrike Koermoeczi, Imke Lohmann, Margit Mitterbauer, MD, Peter Kalhs, MD, Werner Rabitsch, MD, Christoph Zielinski, MD, Winfried F. Pickl, MD

Blood (2006) 108 (11): 2881.

https://doi.org/10.1182/blood.V108.11.2881.2881

Published: 2006

Journal Articles

Heme Oxygenase-1 (HO-1)/Heat Shock Protein 32 (Hsp32) as a Novel Survival Factor and Target in AML.

Michael Kneidinger, MD, Karoline V. Gleixner, md, Rudin Kondo, md, Puchit Samorapoompichit, md, Anja Vales, md, Maria T. Krauth, md, Matthias Mayerhofer, md, Alexander Gruze, Winfried F. Pickl, md, Khaled Greish, Alexandra Boehm, md, Wolfgang R. Sperr, md, Hiroshi Maeda, md, phd, Peter Valent, md

Blood (2006) 108 (11): 1901.

https://doi.org/10.1182/blood.V108.11.1901.1901

Published: 2006

Journal Articles

The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Karoline V. Gleixner, MD, Maria-Theresa Krauth, MD, Alexander Gruze, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2006) 108 (11): 1437.

https://doi.org/10.1182/blood.V108.11.1437.1437

Published: 2006

Journal Articles

Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Karoline V. Gleixner, Maria-Theresa Krauth, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Hermine Agis, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2005) 106 (11): 3516.

https://doi.org/10.1182/blood.V106.11.3516.3516

Published: 2005

Journal Articles

Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis.

Alexandra Boehm, MD, Stefan Florian, MD, Karoline Gleixner, Karoline Sonneck, MD, Karl J. Aichberger, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Peter Valent, MD, Wolfgang R. Sperr, MD

Blood (2005) 106 (11): 3518.

https://doi.org/10.1182/blood.V106.11.3518.3518

Published: 2005

Journal Articles

In Vitro and In Vivo Antileukemic Effects of the mTOR-Targeting Drug Rapamycin in Patients with Imatinib-Resistant CML.

Matthias Mayerhofer, MD, Alexandra Boehm, MD, Karl J. Aichberger, MD, Harald Esterbauer, MD, PhD, Sophia Derdak, MD, Winfried F. Pickl, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2005) 106 (11): 4834.

https://doi.org/10.1182/blood.V106.11.4834.4834

Published: 2005

Journal Articles

BCR/ABL Induces Expression of Histidine Decarboxylase and Synthesis of Histamine in CML Cells.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Maria-Theresa Krauth, MD, Anna Vales, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2005) 106 (11): 4835.

https://doi.org/10.1182/blood.V106.11.4835.4835

Published: 2005

Journal Articles

Low-Level Expression of the Tumor Suppressor Bim in CML Cells: Role of BCR/ABL, Delineation of Underlying Signaling Pathways, and Re-Expression by Imatinib, AMN107, and Proteasome Inhibitors.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Maria-Theresa Krauth, MD, Anna Vales, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Edgar Selzer, MD, Michael Deininger, MD, PhD, Brian J. Druker, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2005) 106 (11): 1987.

https://doi.org/10.1182/blood.V106.11.1987.1987

Published: 2005

Journal Articles

Targeting of mTOR in AML Is Associated with Decreased Growth of Leukemic Cells and Downregulation of VEGF.

Alexandra Boehm, MD, Karl J. Aichberger, MD, Matthias Mayerhofer, MD, Maria-Theresa Krauth, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Puchit Samorapoompichit, MD, Christian Sillaber, MD, Stefan Florian, Karoline Sonneck, MD, Wolfgang R. Sperr, MD, Peter Valent, MD

Blood (2004) 104 (11): 2544.

https://doi.org/10.1182/blood.V104.11.2544.2544

Published: 2004

Journal Articles

Cooperative Anti-Leukemic Effects of Imatinib and Mcl-1 Antisense: Identification of Mcl-1 as a Novel Target in CML.

Karl J. Aichberger, MD, Matthias Mayerhofer, MD, Maria-Theresa Krauth, MD, Hans Skvara, MD, Stefan Florian, MD, Karoline Sonneck, MD, Cahit Akgul, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Brett P. Monia, PhD, Richard Moriggl, PhD, Peter Valent, MD, Christian Sillaber, MD

Blood (2004) 104 (11): 2972.

https://doi.org/10.1182/blood.V104.11.2972.2972

Published: 2004

Journal Articles

The Heme Oxygenase-1-Targeting Compound PEG-ZnPP Inhibits Growth of Imatinib-Resistant BCR/ABL-Transformed Cells.

Matthias Mayerhofer, MD, Karl J. Aichberger, MD, Stefan Florian, Maria-Theresa Krauth, MD, Sophia Derdak, PhD, Harald Esterbauer, PhD, MD, Oswald Wagner, MD, Winfried F. Pickl, MD, Edgar Selzer, MD, Michael W. Deininger, PhD, MD, Brian J. Druker, MD, Khaled Greish, PhD, Hiroshi Maeda, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2004) 104 (11): 1986.

https://doi.org/10.1182/blood.V104.11.1986.1986

Published: 2004

NARROW

Effects of Ponatinib and Other Novel TKI On Growth, Survival, and Function of Neoplastic Eosinophils Carrying FIP1L1/Pdgfra

5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells,

The Heat Shock Protein 32 (Hsp32)/HO-1-Targeting Drug SMA-ZnPP and the Triterpenoid CDDO-Me Exert Synergistic Growth-Inhibitory Effects on TKI-Resistant Leukemic Cells in Ph+ CML

Bosutinib Blocks Lyn and Btk Activation and Synergizes with the KIT D816V-Targeting Drug Midostaurin in Inducing Apoptosis in Neoplastic Human Mast Cells.

Effects of Bosutinib (SKI-606) in CML: Kinase Target Profile, Effects on BCR/ABL Mutants, and Synergism with Dasatinib in T315I+ Cells

Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL).

Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax ® ) on Growth and Viability of Canine and Human Neoplastic Mast Cells

Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis.

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

Circulating B-Lymphocyte Subpopulations as Novel Biomarker for Measuring Activity of Chronic Graft-Versus-Host Disease.

Heme Oxygenase-1 (HO-1)/Heat Shock Protein 32 (Hsp32) as a Novel Survival Factor and Target in AML.

The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells.

Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.

Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis.

In Vitro and In Vivo Antileukemic Effects of the mTOR-Targeting Drug Rapamycin in Patients with Imatinib-Resistant CML.

BCR/ABL Induces Expression of Histidine Decarboxylase and Synthesis of Histamine in CML Cells.

Low-Level Expression of the Tumor Suppressor Bim in CML Cells: Role of BCR/ABL, Delineation of Underlying Signaling Pathways, and Re-Expression by Imatinib, AMN107, and Proteasome Inhibitors.

Targeting of mTOR in AML Is Associated with Decreased Growth of Leukemic Cells and Downregulation of VEGF.

Cooperative Anti-Leukemic Effects of Imatinib and Mcl-1 Antisense: Identification of Mcl-1 as a Novel Target in CML.

The Heme Oxygenase-1-Targeting Compound PEG-ZnPP Inhibits Growth of Imatinib-Resistant BCR/ABL-Transformed Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only